OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial
Daily squirts of a safe, over-the-counter allergy nasal spray may prevent COVID-19 infections from taking hold, according to results published Tuesday in JAMA Internal Medicine. In a mid-staged trial, the spray appeared to reduce infections by promising 67 percent, though a larger trial will need to confirm that robust efficacy. The trial was a randomized, double-blind, placebo-controlled Phase 2 trial conducted by researchers at Germany's Saarland University between March 2023 and July 2024. T